GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Total Current Liabilities

Cerevel Therapeutics Holdings (STU:673) Total Current Liabilities : €77.38 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cerevel Therapeutics Holdings's total current liabilities for the quarter that ended in Mar. 2024 was €77.38

Cerevel Therapeutics Holdings Total Current Liabilities Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Total Current Liabilities Chart

Cerevel Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
13.39 24.29 37.65 68.50 84.53

Cerevel Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.80 60.51 73.87 84.53 77.38

Cerevel Therapeutics Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cerevel Therapeutics Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=62.524+3.121
+Other Current Liabilities+Current Deferred Liabilities
=18.883+0
=84.53

Cerevel Therapeutics Holdings's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=66.359+3.234
+Other Current Liabilities+Current Deferred Liabilities
=7.783+0
=77.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cerevel Therapeutics Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Total Current Liabilities
Comparable Companies
PCVX HALO BBIO IMVT MRTX ABCZF ASND ACAD IMGN BPMC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CERE:USA
Address
222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141
Website
https://www.cerevel.com
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines